Department of Obstetrics and Gynecology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
Endocr Rev. 2019 Aug 1;40(4):1048-1079. doi: 10.1210/er.2018-00242.
Pelvic endometriosis is a complex syndrome characterized by an estrogen-dependent chronic inflammatory process that affects primarily pelvic tissues, including the ovaries. It is caused when shed endometrial tissue travels retrograde into the lower abdominal cavity. Endometriosis is the most common cause of chronic pelvic pain in women and is associated with infertility. The underlying pathologic mechanisms in the intracavitary endometrium and extrauterine endometriotic tissue involve defectively programmed endometrial mesenchymal progenitor/stem cells. Although endometriotic stromal cells, which compose the bulk of endometriotic lesions, do not carry somatic mutations, they demonstrate specific epigenetic abnormalities that alter expression of key transcription factors. For example, GATA-binding factor-6 overexpression transforms an endometrial stromal cell to an endometriotic phenotype, and steroidogenic factor-1 overexpression causes excessive production of estrogen, which drives inflammation via pathologically high levels of estrogen receptor-β. Progesterone receptor deficiency causes progesterone resistance. Populations of endometrial and endometriotic epithelial cells also harbor multiple cancer driver mutations, such as KRAS, which may be associated with the establishment of pelvic endometriosis or ovarian cancer. It is not known how interactions between epigenomically defective stromal cells and the mutated genes in epithelial cells contribute to the pathogenesis of endometriosis. Endometriosis-associated pelvic pain is managed by suppression of ovulatory menses and estrogen production, cyclooxygenase inhibitors, and surgical removal of pelvic lesions, and in vitro fertilization is frequently used to overcome infertility. Although novel targeted treatments are becoming available, as endometriosis pathophysiology is better understood, preventive approaches such as long-term ovulation suppression may play a critical role in the future.
盆腔子宫内膜异位症是一种复杂的综合征,其特征是雌激素依赖性慢性炎症过程,主要影响盆腔组织,包括卵巢。当脱落的子宫内膜组织逆行进入下腹腔时,就会发生子宫内膜异位症。子宫内膜异位症是女性慢性盆腔疼痛的最常见原因,并且与不孕有关。腔内子宫内膜和子宫外子宫内膜异位组织中的潜在病理机制涉及编程不良的子宫内膜间充质祖细胞/干细胞。尽管构成子宫内膜异位病变大部分的子宫内膜异位症基质细胞不携带体细胞突变,但它们表现出特定的表观遗传异常,改变关键转录因子的表达。例如,GATA 结合因子-6 过表达将子宫内膜基质细胞转化为子宫内膜异位症表型,而甾体生成因子-1 过表达导致雌激素过度产生,通过病理水平的雌激素受体-β驱动炎症。孕激素受体缺乏导致孕激素抵抗。子宫内膜和子宫内膜异位症上皮细胞群体也存在多种癌症驱动突变,例如 KRAS,这可能与盆腔子宫内膜异位症或卵巢癌的发生有关。尚不清楚表观遗传缺陷的基质细胞与上皮细胞中的突变基因之间的相互作用如何导致子宫内膜异位症的发病机制。通过抑制排卵月经和雌激素产生、环氧化酶抑制剂以及手术切除盆腔病变来管理与子宫内膜异位症相关的盆腔疼痛,并且经常使用体外受精来克服不孕。尽管新型靶向治疗方法正在出现,但随着对子宫内膜异位症病理生理学的更好理解,长期排卵抑制等预防方法可能在未来发挥关键作用。